



International Conference & Exhibition on Vaccines & Vaccination

22-24 Nov 2011 Philadelphia Airport Marriott, USA

Acceptability of human papillomavirus vaccine among women in China: A literature review of surveys among 23,700 women

Lina Hu² and Lei Yu¹

¹Sichuan University, China

²Chongqing Medical University, China

The prevalence of papillomavirus virus (HPV) is high in China. Nonetheless, HPV vaccine is not available in China due to licensing issue. We reviewed 11 available studies on the willingness of HPV vaccination among women in China to explore public interest and possible strategies for setting up vaccination programs. A total of 23,700 women from 15 provinces in China participated in the studies. Questionnaire-based survey was used in all studies. Seven studies were conducted in urban areas, and 4 were in both urban and rural regions. Participants included general public and healthcare providers which were recruited from either local communities or medical institutions. Overall knowledge on HPV was low amongst all participants except healthcare providers. In all the studies, 32.14% to 98.4% women were willing to accept HPV vaccine, and 53.64% to 86.4% women who have daughters supported vaccination for their daughters. No differences of acceptability existed between women from urban and from rural areas. In the only study where healthcare providers were included, a similar acceptance rate to other participants included in the same study was observed. Predictive factors of acceptance included education status, age and economical status. Though low awareness of HPV, there is high acceptance for HPV vaccine among women in China. Key elements for successful implementation of HPV vaccine in China include education programs, availability of HPV vaccine, and cost.

Biography

Dr. Hu is a professor and the chief of the Obstetrics and Gynecology department in the Second Affiliated Hospital of Chongqing Medical University, China. She is a committee member of the Society of Obstetrics and Gynecology, China Medical Association. She has numerous publications and has conducted 10 key projects as principal investigator.

Dr. Lei Yu has graduated from Westchina Medical School, Sichuan University in China and now is a Master Candidate in Sichuan University. Her research interests include the introduction of HPV vaccine as prevention strategy of cervical cancer in developing countries.